Product Information Update – Mifegyne 200mg tablets (Mifepristone) PA22946/001/001

Notice type: 3rd Party Publications

Date: 20/12/2022

This notice is to inform healthcare professionals about an update to prescribing information. In the case of medical termination of intrauterine pregnancy, a dose adjustment to a higher dose (600 mg) is advised where the patient is being treated concomitantly with CYP3A4 inducers.

Please see the document linked below for further information.



Product name or type:
Mifegyne 200mg tablets (Mifepristone) PA22946/001/001


Authorisation Holder:
Nordic Pharma


Further Information:

Product Information Update – Mifegyne 200mg tablets (Mifepristone) PA22946/001/001 – 20 December 2022 




« Back